Completed PHASE2 INTERVENTIONAL NCT00290212

Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause

Phase II Study of Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause: a Randomised Double Blind Placebo-Controlled Trial

Sponsor: Haukeland University Hospital

Conditions Perimenopausal Bone Loss

Interventions Natto capsules (food suppl.) cont. 360 microg. vit K2/day Placebo capsules

Updated 5 times since 2017 Last updated: Jan 23, 2008 Started: Jan 31, 2006 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Perimenopausal Bone Loss, this trial is completed. The trial is conducted by Haukeland University Hospital and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Haukeland University Hospital
The International Osteoporosis Foundation
University Hospital of North Norway
University of Tromso

Data source: University Hospital of North Norway

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bergen, Norway
• Tromsø, Norway